Reddel, Helen K
Levy, Mark L
,
Article History
Received: 18 February 2015
Revised: 10 May 2015
Accepted: 23 June 2015
First Online: 30 July 2015
Competing interests
: HKR has been a member of advisory boards for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis; is a member of a data safety monitoring board for AstraZeneca, GlaxoSmithKline, Merck and Novartis; has provided consulting for AstraZeneca and GlaxoSmithKline; has prepared and delivered independent medical education at symposia funded by Aerocrine, AstraZeneca, GlaxoSmithKline, Mundipharma, Novartis and Teva; and has received unrestricted research grants from AstraZeneca and GlaxoSmithKline. MLL reports personal fees and non-financial support from GlaxoSmithKline, personal fees and non-financial support from Novartis, personal fees from Clement Clarke International, personal fees and non-financial support from Teva, personal fees from AstraZeneca, non-financial support from GINA, personal fees and non-financial support from Chiesi, and personal fees and non-financial support from Consorzio Futuro In Ricerca.